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Hepatitis C (HC) disease is an important public 
health problem, with a high potential for chronicity 
(85%), cirrhosis and hepatocellular carcinoma (Imbert-
Bismut et al. 2001). Hepatocellular damage occurs when 
the infected cell is recognized by the immune system 
and destroyed. This process is extremely variable and 
dynamic, resulting in different intensities of hepatic ne-
crosis and inflammation. Thus, this continuous inflam-
matory process is responsible for fibrogenesis (Missale 
et al. 1996, Strauss 2001, Poynard et al. 2003). During 
HC virus (HCV) infection, male sex, age, alcohol con-
sumption, presence of other viruses (HIV, hepatitis B 
virus), schistosomiasis and immunological status have 
been linked to histological severity (Pessione et al. 1998, 
Kamal et al. 2006).
Schistosoma mansoni infection is a chronic helmin-
thic disease that develops primarily because of chronic 
granulomatous inflammation against parasite eggs in the 
liver, which results in hepatic periportal fibrosis, portal 
hypertension and sometimes death by digestive bleeding 
of esophageal varices, present in the severe hepatosplen-
ic clinical form. Granulomas in schistosomiasis depend 
predominantly on CD4+ T cells and represent a form of 
delayed-type hypersensitivity (Abath et al. 2006).
Andrade (1962) and Dusek et al. (1965) emphasized that 
the association between chronic hepatitis and schistosomi-
asis aggravated liver disease. Blood transfusions secondary 
to digestive haemorrhage due to schistosomiasis portal hy-
pertension is one of the major causes of HC transmission to 
schistosomiasis patients in Brazil (Cid et al. 1985).
HC and schistosomiasis co-infection is common in 
many developing countries, including Brazil, and ac-
cording to Kamal et al. (2004, 2006) shows a specific 
clinical, virological and histological pattern character-
ized by virus persistence with high HCV RNA titres and 
higher necroinflammatory and fibrosis scores in liver 
biopsies. In addition, these patients exhibit a poor inter-
feron therapy response and accelerated hepatic fibrosis 
(Kamal et al. 2006).
Fibrosis is the major cause of mortality and morbid-
ity related to both schistosomiasis and HC, although the 
pattern of fibrosis and underlying immunological mech-
anisms are different (Abath et al. 2006). 
Liver biopsy is the gold-standard method for the as-
sessment of fibrosis; however, it is an invasive proce-
dure and is potentially dangerous (Imbert-Bismut et al. 
2001, Myers et al. 2002, Wai et al. 2003, Poynard et al. 
2005). In addition, it is a costly procedure and requires a 
physician, support staff and an experienced pathologist. 
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Liver biopsy is the gold-standard method to stage fibrosis; however, it is an invasive procedure and is potentially 
dangerous. The main objective of this study was to evaluate biological markers, such as cytokines IL-13, IFN-γ, 
TNF-α and TGF-β, platelets, bilirubins (Bil), alanine aminotransferase (ALT) and aspartate aminotransferase (AST), 
total proteins, γ-glutamil transferase (γ-GT) and alkaline phosphatase (AP), that could be used to predict the sever-
ity of hepatic fibrosis in schistosomiasis and hepatitis C (HC) as isolated diseases or co-infections. The following 
patient groups were selected: HC (n = 39), HC/hepatosplenic schistosomiasis (HSS) (n = 19), HSS (n = 22) and a 
control group (n = 13). ANOVA and ROC curves were used for statistical analysis. P < 0.05 was considered signifi-
cant. With HC patients we showed that TNF-α (p = 0.020) and AP (p = 0.005) could differentiate mild and severe 
fibrosis. With regard to necroinflammatory activity, AST (p = 0.002), γ-GT (p = 0.034) and AP (p = 0.001) were the 
best markers to differentiate mild and severe activity. In HC + HSS patients, total Bil (p = 0.008) was capable of dif-
ferentiating between mild and severe fibrosis. In conclusion, our study was able to suggest biological markers that 
are non-invasive candidates to evaluate fibrosis and necroinflammatory activity in HC and HC + HSS. 
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Furthermore, a percutaneous liver biopsy can generate 
sampling errors from the small size of the biopsy and 
variability in fibrosis interpretation, giving a static view 
of the necroinflammatory and fibrotic process since a 
liver biopsy represents only a small part of the whole 
organ (Lichtinghagen & Bahr 2004). 
As a result of these limitations, several studies have 
emerged in an attempt to develop accurate and reliable 
non-invasive means to assess the severity of hepatic fi-
brosis in HC patients, since knowledge of the stage of liver 
fibrosis is essential for prognosis and decisions on antivi-
ral therapy (Imbert-Bismut et al. 2001, Myers et al. 2002, 
Poynard et al. 2002, 2005, Freeman et al. 2003, Morais et 
al. 2006, Gressner et al. 2007, Correia et al. 2009).
 Although there is no indicator of human schisto-
somiasis in liver biopsy, use of non-invasive biologi-
cal markers to predict fibrosis severity is important for 
monitoring the transition to the severe forms of the dis-
ease and prognosis of these patients. In the areas where 
access to health care services is limited, these markers 
are also essential to evaluate fibrosis regression after 
treatment (Burchard et al. 1998, Ricard-Blum et al. 1999, 
Köpke-Aguiar et al. 2002). Most of the studies regarding 
biological serum markers of fibrosis have focused on HC 
or schistosomiasis as an isolated disease. The main ob-
jective of this study was to correlate levels of biological 
serum markers with the prediction of clinically signifi-
cant fibrosis and necroinflammatory activity in HC and 
schistosomiasis, not only as isolated diseases, but also as 
co-infections.
PATIENTS, MATERIALS AND METHODS
Subject selection - This study included 80 patients 
aged 18-65 years old, selected at the outpatient facilities 
of the Hospital das Clínicas da universidade Federal de 
Pernambuco (uFPe), Recife, Pernambuco (Pe), Brazil. 
The following groups were studied: HC (n = 39); HC plus 
hepatosplenic schistosomiasis (HSS) (n = 19) and HSS 
(n = 22). Liver biopsies, ultrasonography, parasitological 
stool exams and blood tests for biological markers of fi-
brosis were performed. All patients were tested for hepa-
titis B (HBsAg and anti-HBc), HIV (anti-HIV) and HCV 
(anti-HCV) (Gretch 1997). Diagnosis of HC in patients 
was confirmed by detection of viral RNA (zeuzem et al. 
1994) and genotyping (Stuyver et al. 1996).
For schistosomiasis patients, the diagnosis was con-
firmed by ultrasonography and three parasitological stool 
examinations. These patients were selected after treatment; 
however, HC patients were selected before treatment.
Patients with the following conditions were ex-
cluded from the study: other causes of liver disease, 
liver transplantation, prior interferon therapy, immu-
nosuppressive therapy, hepatitis B, HIV, insufficient 
liver tissue samples for staging of fibrosis and alcohol 
consumption (> 30 g/day). 
The control group (n = 13), ranging from 21-57 years 
old, was from non-endemic areas of Pe and was selected 
at Centro de Pesquisas Aggeu Magalhães. These indi-
viduals had three negative parasitological stool exami-
nations for S. mansoni, no history of contact with con-
taminated water and negative anti-HCV.
All patients and control group individuals signed an 
informed consent form and the study was reviewed and 
approved by the ethical Committee of the Centro de Pes-
quisas Aggeu Magalhães-Fiocruz, Recife, Pe, Brazil.
Fibrosis stage and necroinflammatory activity grade 
- HC and HC + HSS patients underwent percutaneous 
liver biopsy at Hospital das Clínicas da uFPe. Histologi-
cal features of liver biopsy were analysed according to 
the Metavir scoring system (Bedossa & Poynard 1996). 
Fibrosis was staged on a scale as follows: F0 (no fibro-
sis), F1 (portal fibrosis without septa), F2 (few septa), 
F3 (numerous septa without cirrhosis) and F4 (cirrhosis). 
The intensity of necroinflammation was graded on a 
scale as follows: A0 (no activity), A1 (mild activity), A2 
(moderate activity) and A3 (severe activity).
In addition, HSS and HC + HSS patients had their de-
gree of fibrosis analysed by ultrasonography according to 
the Cairo scoring system (WHo 1990) as follows: degree 
I (mild periportal fibrosis), degree II (moderate periportal 
fibrosis) and degree III (severe periportal fibrosis). 
Determination of serum levels of biological markers 
- Blood samples (15 mL) were collected using a vacuum 
system and disposable needles from all patients and con-
trol group individuals for assessing the serum levels of 
biological markers. 
In this study, the biological markers were divided 
into biochemical markers, platelets and cytokines in-
volved with inflammation and fibrogenesis. 
Determination of serum levels of biochemical mark-
ers - The following markers were assessed for the study: 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), total proteins, bilirubins, γ-glutamil trans-
ferase (γ-GT) and alkaline phosphatase (AP). 
The serum levels of ALT, AST, total proteins, bili-
rubins, γ-GT and AP were determined by the ARCHI-
TeCT c8000 (Abbott) using Abbott reagent kits at the 
laboratory of the Hospital das Clínicas da uFPe.
Platelet count - Platelet counts were determined us-
ing the Cell-Dyn 3500 (Abbott) at the laboratory of the 
HC-uFPe.
Determination of cytokine serum levels - The serum 
levels of cytokines IL-13, IFN-γ, TNF-α and TGF-β were 
measured using the enzyme linked immunosorbent as-
say Quantikine kit (R&D system) following the manu-
facturer’s instructions.
 
Statistical methods - HC and HC + HSS patients 
were divided into two groups according to the severity 
of their histological lesions: no significant or mild fibro-
sis (F0-F1) and significant or severe fibrosis (F2-F4). 
The primary outcome was the identification of patients 
with clinically significant fibrosis. This dichotomization 
was performed because F2 fibrosis is generally consid-
ered the threshold for the initiation of antiviral treatment 
of chronic HC. 
These patients were also analysed according to the 
presence of necroinflammatory activity and divided into 
two groups: no significant activity (A0-A1) and signifi-
cant activity (A2-A3).
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HSS and HC + HSS patients were statistically analy-
sed into two groups according to the degree of fibrosis as 
evaluated by ultrasonography as follows: mild fibrosis 
(degree I) and severe fibrosis (degrees II and III).
The statistical analyses were performed using the soft-
ware SPSS for Windows version 12.0, 2004 (Chicago, 
uSA). P values of 0.05 or less were considered significant.
The ANoVA was used for comparison of serum lev-
els of biological markers between the four study groups. 
For every biological marker, receiving operating 
characteristics (RoC) curves were built to establish the 
best cut-off value that would correlate with severe fi-
brosis and severe necroinflammatory activity for each 
group of patients studied.
RESULTS
Biological serum marker levels - For the HC + HSS 
group (Table I), serum levels of AST, ALT, AP and 
γ-GT were higher in comparison to the control group (p 
= 0.001, p = 0.014, p = 0.029 and p = 0.003, respective-
ly). In addition, the serum levels of AST were higher in 
comparison to the HSS group (p = 0.035). Also, the AP 
levels were higher than in the HC group (p = 0.023). 
Total and direct bilirubins were higher when compared 
with the HC group and control group (p < 0.001 for 
both) (Table II). 
Levels of γ-globulin (Table III) were also higher in 
the HC + HSS group in comparison to the HC (p < 0.001) 
and HSS (p = 0.035) groups, as well as the control group 
(p < 0.001). Albumin levels (Table III) were lower in the 
HC + HSS group than in the HC group (p = 0.014), HSS 
group (p = 0.013) and control group (p < 0.001). 
For the HC group (Table I), ALT levels were higher 
than in the HSS (p = 0.010) and control groups (p < 
0.001). AP and γ-GT were lower than in the HSS group 
(p = 0.012 for both). In addition, AST levels were higher 
than in the control group (p = 0.004). Also, γ-GT levels 
were higher than in the control group (p = 0.028). Total 
bilirubins (Table II) in the HC group were higher when 
compared with the control group (p < 0.013) mainly 
due to indirect bilirubin (p = 0.023).
The HSS group compared with control group showed 
higher levels of AP, γ-GT (Table I), TB (Table II) and 
γ-globulins (Table I) (p = 0.013, p < 0.001, p = 0.001 and 
p = 0.043, respectively). 
Serum levels of the cytokines IL-13, TGF-β, IFN-γ 
and TNF-α were not significantly different among the 
study groups (p > 0.05).
Correlation of biological serum marker levels to pre-
dict severe fibrosis and necroinflammatory activity in 
HC patient groups - Fibrosis stages and necroinflamma-
tory activity grades obtained through histologies of liver 
biopsy using the Metavir scoring system were studied 
as described in the Patients, Materials and Methods sec-
tion. our results showed that 47.2% of HC patients had 
mild fibrosis and necroinflammatory activity and 52.8% 
had severe fibrosis and necroinflammatory activity.
When we compared the area under the curve (AuC) 
for the RoC of the serum levels of the biological markers 
in order to predict mild or severe fibrosis, it was found 
TABLe I
Comparisons of the study groups with alanine  
aminotransferase (ALT), aspartate aminotransferase (AST),  
alkaline phosphatase (AP) and γ-glutamil transferase (γ-GT) levels
Groups
p value
ALT AST AP γ-GT
HC/HSS x HC 0.119 0.375 0.023a 0.182
HC/HSS x HSS 0.208 0.035a 0.502 0.173
HC/HSS x control 0.014a 0.001a 0.029a 0.003a
HC x HSS 0.010a 0.100 0.012a 0.012a
HC x control < 0.001a 0.004a 0.633 0.028a
HSS x control 0.330 0.384 0.013a < 0.001a
a: (p < 0.05) is considered statistically significant; control: 
control group; HC: hepatitis C patients; HC/hepatitis C plus 
hepatosplenic schistosomiasis (HSS) patients. 
TABLe II
Comparisons of the study groups with total bilirubins (TB), 




HC/HSS x HC < 0.001a < 0.001a 0.038a
HC/HSS x HSS 0.305 0.123 0.704
HC/HSS x control < 0.001a < 0.001a < 0.001a
HC x HSS 0.077 0.083 0.216
HC x control 0.013a 0.113 0.023a
HSS x control 0.001a 0.008a 0.006a
a: (p < 0.05) is considered statistically significant; control: 
control group; HC: hepatitis C patients; HC/hepatitis C plus 
hepatosplenic schistosomiasis (HSS) patients. 
TABLe III





HC/HSS x HC 0.014a < 0.001a
HC/HSS x HSS 0.013a 0.035a
HC/HSS x control < 0.001a < 0.001a
HC x HSS 0.422 0.549
HC x control 0.004a 0.046a
HSS x control 0.124 0.043a
a: (p < 0.05) is considered statistically significant; control: 
control group; HC: hepatitis C patients; HC/hepatitis C plus 
hepatosplenic schistosomiasis (HSS) patients.
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that TNF-α and AP showed statistically significant AUC 
(p = 0.020 and p = 0.005, respectively). The best diagnos-
tic values of these markers (cut-offs) were reported us-
ing sensitivity, specificity, positive predictive value and 
negative predictive value and are shown in Table IV.
For the prediction of severe necroinflammatory ac-
tivity, AST, AP and γ-GT showed statistically signifi-
cant AuC. The best cut-off levels and diagnostic values 
of these markers can be seen in Table V. 
Correlation of biological marker serum levels to pre-
dict severe fibrosis and severe necroinflammatory activ-
ity in the HC plus schistosomiasis group - In this group 
of patients, the gold-standard classification of fibrosis 
stage was the histology of liver biopsies using the Meta-
vir scoring system, since only a small number of patients 
had ultrasonography data (5 patients missing data).
our results showed that 31.2% of HC + HSS patients 
had mild fibrosis and necroinflammatory activity and 
68.8% had severe fibrosis and necroinflammatory activity.
When analysing the results, we found that total 
bilirubin showed a statistically significant AuC RoC 
curves for predicting severe fibrosis (Table VI). In addi-
tion, platelets, ALT, AST, total bilirubin and γ-globulin 
showed statistically significant AuC RoC curves for 
predicting severe necroinflammatory activity in these 
patients (Table VII).
Correlation of biological marker serum levels to predict 
severe fibrosis in the schistosomiasis patient group - The 
degree of fibrosis analysed through ultrasonography 
using the Cairo scoring system, as described in the Pa-
tients, Materials and Methods section, was compared 
with biological marker serum levels. 
of schistosomiasis patients, 90.9% presented with 
severe fibrosis according to ultrasonography analysis. 
Platelet counts were used to build RoC curves to 
predict severe fibrosis in schistosomiasis patients. The 
results showed no statistically significant AuC RoC 
curves. The other biological markers could not be analy-
sed due to the small number of patients. 
Comparative analysis between HC and HC + HSS 
groups and HSS and HC + HSS groups relative to fi-
brosis degree - our results showed no statistically sig-
nificant differences when we compared the degree of 
fibrosis among the study groups (p > 0.05).
DISCUSSION 
Hepatic fibrosis in HC and schistosomiasis co-infections 
can progress to cirrhosis and its complications, such as he-
patocellular carcinoma (Köpke-Aguiar et al. 2002, Myers 
et al. 2002, Shiha & zalata 2002, Kamal et al. 2006). 
The assessment of the presence and severity of liver 
fibrosis is essential in determining treatment strategies, 
response to treatment, prognosis and the potential risk 
for complications in patients with chronic liver disease. 
Liver biopsy, the gold-standard method for diagnos-
ing the severity of necroinflammatory activity and fibro-
sis, is an invasive tool and it is associated with rare but 
serious complications, such as bleeding, pneumothorax 
and perforation of the colon and gallbladder (Thuluvath 
TABLe IV
Performance of biological markers to discriminate between no significant or mild fibrosis  
and significant or severe fibrosis in hepatitis C patients group
Biomarker






Positive predictive  
value (%)
Negative predictive  
value (%)
TNF-α 0.728 ≥ 3.23 63.16 88.24 85.71 68.18
Alkaline phosphatase 0.774 ≥ 11.90 84.21 58.82 69.57 76.92
only the discriminative tests are displayed; CI: confidence interval. 
TABLe V
Performance of biological markers to discriminate between no significant activity necroinflammatory  
and significant activity necroinflammatory in hepatitis C patients group
Biomarker






Positive predictive  
value (%)
Negative predictive  
value (%)
Aspartate aminotransferase 0.8 ≥ 47.5 84.21 70.59 76.19 80
Alkaline phosphatase 0.833 ≥ 104 63.16 100 100 70.83
γ-glutamil transferase 0.707 ≥ 107 52.63 88.24 83.33 62.13
only the discriminative tests are displayed; CI: confidence interval. 
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& Krok 2006). Furthermore, because of its risks, cost 
and inconvenience, liver biopsy is certainly not the ideal 
procedure for repeated assessment of disease progres-
sion, especially during chronic HC (Castera et al. 2008, 
Fontana et al. 2008).
In light of this, developing non-invasive tests that can 
accurately predict fibrosis stage and progression over 
time is a high priority and a growing medical necessity. 
Among these non-invasive tests are biological markers 
in serum, used either individually or in combination 
and alternative imaging techniques, such as ultrasound, 
magnetic resonance imaging and transient elastography 
(Sandrin et al. 2003, ziol et al. 2005, Gressner et al. 2007, 
Castera et al. 2008).
Conventional liver function tests reflect hepatocyte 
damage as ALT and AST, whereas biliary obstructions 
can be studied by bilirubin and AP and biosynthetic 
function by albumin and prothrombin time. Although 
these tests provide important information on some as-
pects of liver function, they do not assess the activity 
of the fibrogenic process, but can indicate the stage of 
fibrosis (Gressner et al. 2007, Rossi et al. 2007). 
However, biomarkers that have a direct relation to 
extracellular matrix protein synthesis or turnover, such 
as the amino-terminal peptide of III procollagen, are be-
lieved to primarily reflect fibrogenesis activity (Gress-
ner et al. 2007).
Recent studies suggest that some of these biological 
serum markers of fibrosis, used in combination to form 
fibrosis scores, such as Fibrotest and Actitest (Poynard 
et al. 2002, 2004, 2005), Forns index (Forns et al. 2002) 
and AST/platelets ratio (Wai et al. 2003), may provide 
important disease staging information like the presence 
or absence of advanced fibrosis or cirrhosis. Although 
widely available, these scores have been found to be poor 
at predicting intermediate levels of fibrosis and there is a 
risk of false-positive and false-negative results (Poynard 
et al. 2005).
Most scores were developed and tested in HCV pa-
tients and, thus, their extrapolation to non-HCV aetiolo-
gies of fibrosis must be considered with caution (Gress-
ner et al. 2007).
In this context, this study aimed to evaluate biologi-
cal serum markers that could be used to predict the se-
verity of liver fibrosis in HC and schistosomiasis as iso-
lated diseases or co-infections.
According to Kamal et al. (2004, 2006), patients with 
HC and schistosomiasis co-infections exhibit higher 
necroinflammatory and hepatic fibrosis in liver biopsies 
with a significant hepatic fibrosis progression rate com-
pared with HCV infection alone. They also found that 
levels of fibrosis markers and cytokines evaluated in this 
study showed a strong correlation with disease progres-
sion. our results showed no statistically significant dif-
ferences in fibrosis degree on histology evaluation when 
fibrosis of HC + HSS patients were compared to HC 
patients alone. In addition, no statistically significant 
differences were found comparing fibrosis degree by ul-
trasonography in HC + HSS and HSS groups. However, 
higher levels of fibrosis serum markers, such as AST, 
TABLe VI
Performance of biological markers to discriminate between no significant or mild fibrosis and significant  
or severe fibrosis in hepatitis C plus schistosomiasis patients group 
Biomarker






Positive predictive  
value (%)
Negative predictive  
value (%)
Total bilirubins 0.845 ≥ 1.05 72.73 100 100 62.5
only the discriminative tests are displayed; CI: confidence interval. 
TABLe VII
Performance of biological markers to discriminate between no significant activity necroinflammatory  
and significant activity necroinflammatory in hepatitis C plus schistosomiasis patients group
Biomarker








Negative predictive  
value (%)
Platelets 0.909 ≤ 195 100 80 91.67 100
Alanine aminotransferase 0.836 ≥ 41.5 100 60 84.62 100
Aspartate aminotransferase 0.809 ≥ 88.5 54.55 100 100 50
Globulin 0.855 ≥ 1.76 81.82 100 100 71.43
only the discriminative tests are displayed; CI: confidence interval. 
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AP, bilirubin and γ-globulin, were found in HC + HSS 
patients in comparison with HC and HSS alone, suggest-
ing that these markers could differentiate co-infected 
from the mono-infected patients (Kamal et al. 2006).
In addition, HC patients produced higher levels of 
ALT in comparison to HSS patients, indicating that 
necroinflammatory activity and viral replication is pres-
ent in this infection (Pal et al. 2006).
Levels of γ-GT and AP were higher in HSS patients 
in comparison to HC patients. Increased γ-GT serum 
levels in HSS patients may be due the presence of granu-
lomas in the hepatic parenchyma. The AP levels in HSS 
patients are also related to the presence of granulomas in 
the hepatic parenchyma and distortion of the vasculature 
(Barreto 1971, Vianna et al. 1989). These granulomas 
could eventually produce a biliary duct compression by 
raising the levels of γ-GT and this enzyme could be an 
early marker of portal hypertension (Martins & Borges 
1993, Souza et al. 2000, Köpke-Aguiar et al. 2002).
According to our results, γ-GT serum levels were 
also capable of differentiating between mild and severe 
necroinflammatory activity in HC patients with a predic-
tive positive value of 83%. An explanation for this asso-
ciation was not found because levels of this enzyme are 
normally related to severe fibrosis and early cholestasis 
(Martins & Borges 1993, Imbert-Bismut et al. 2001).
Serum levels of the cytokines IL-13, INF-γ, TNF-α 
and TGF-β were not significantly different among the 
study groups (p > 0.05).
Analysing fibrosis stage and necroinflammatory 
activity in each group of patients separately, keeping in 
mind that patients with F2 fibrosis/A2 activity or greater 
are candidates for antiviral therapy, we found in the HC 
group that TNF-α and AP could differentiate between 
mild and severe hepatic fibrosis and that AST, AP 
and γ-GT could differentiate between mild and severe 
necroinflammatory activity.
TNF-α levels in HC patients have been correlated 
with hepatic inflammation (Neuman et al. 2002, Kamal 
et al. 2006) and our study showed the association of this 
cytokine with severe hepatic fibrosis.
AP serum levels could be used as a biological marker 
for both severe fibrosis and necroinflammatory activity in 
HC patients. In other studies, AP has also been associated 
with HC cirrhosis, where fibrosis and inflammation may 
be more severe (Fontana & Lok 2002).
We demonstrated an association between platelet counts 
and severe activity in HC + HSS patients, with a cut-off 
level of  ≤ 195.000/mm3. A moderate decrease in platelet 
count is a marker of portal hypertension present in the HSS 
group and is also a good predictive marker of cirrhosis in 
HCV infection (Renou et al. 2000, Souza et al. 2000). 
In conclusion, our results suggest the inclusion of 
some biological serum marker levels determination in 
clinical practice, prognosis and management of HC and 
schistosomiasis patients and this may be helpful for the 
diagnosis of fibrosis degree and necroinflammatory ac-
tivity. These may not yet be used as a substitute, but as 
a tool to avoid repeated liver biopsy. However, currently 
available biological serum markers should be used with 
caution since neither single nor sets of markers fulfil 
the requirements of an ideal non-invasive biomarker of 
fibrosis that is liver-specific, easy to perform, reliable, 
reproducible with low inter-laboratory variability and 
cost-effective. even the best and most evaluated markers 
do not meet the criteria of an ideal marker.
The future goals of our group are to increase the 
number of subjects in the HC, HC + HSS and HSS 
groups and to build a fibrosis index with the markers 
analysed in this present study to improve diagnostic val-
ues and accurately measure the degree of liver fibrosis 
and necroinflammatory activity in these diseases. Fur-
thermore, we aim to correlate these biological markers 
with other chronic liver diseases and measure the clini-
cal evolution after treatment. 
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